ClinicalTrials.gg
RecruitingNCT07280702COMBoUpdated Sep 1, 2026

Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

A Phase 4 interventional study of Deucravacitinib and Placebo in Psoriatic Arthritis (PsA), sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by University of Texas Southwestern Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Arthritis, Psoriatic with a site in United States — 30 open to participants now, 60 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Planned enrollment
106th of 159
128 · median 228
Started
2026
with 8 others
Phase 4
18 of 194
5 open now
Primary completion
2027-12
later than 37 of 59 live
Registered
185th of 194
by date

Among the 194 studies in Arthritis, Psoriatic with a site in United States, this one is the 106th largest by planned enrollment of the 159 interventional ones that give a count, is one of 9 that started in 2026, is one of 18 in phase 4, reaches primary completion later than 37 of the 59 other live ones, and was the 185th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

30 of the 194 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life.

This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.

03

Conditions studied

  • Psoriatic Arthritis (PsA)

Browse trials for

Keywords

  • Psoriatic Arthritis
  • PsA
  • Deucravacitinib
  • TNF
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-65 with confirmed psoriatic arthritis based on CASPAR criteria.

    • Ability to provide and comply with study procedures.
    • Patients with plaque psoriasis BSA>3% OR PsA with [SJC>2 AND TJC >3] despite stable background anti-TNF therapy for at least 6 months, with or without csDMARDs (i.e MTX, leflunomide, sulfasalazine, hydroxychloroquine).
    • Concurrent use of 1 csDMARD, and/or NSAID, and/or oral is permitted but not required during the study. If such treatment was administered, then participants must meet the following requirements:

      • If on csDMARD (methotrexate [MTX], sulfasalazine [SSZ], leflunomide [LEF], hydroxychloroquine [HCQ]), the participant must have been on it for at least 12 weeks and be on a stable dose for at least 28 days prior to Day 1.

        • If on MTX, the route of administration and dose must be stable and the dose must be ≤ 25 mg/week.
        • If on SSZ, the dose must be ≤ 3 g/day.
        • If on HCQ, the dose must be ≤ 400 mg/day.
        • If on LEF, the dose must be ≤ 20 mg/day. Note: If currently not on MTX, SSZ, or HCQ, the participant must not have received it for at least 28 days prior to Day 1. If currently not on LEF, the participant must not have received it for at least 12 weeks prior to Day 1.
      • If on an NSAID, the participant must be on a stable dose for at least 14 days prior to Day 1.
      • Stable background use of prednisone 15 mg daily or equivalent is permitted. If on oral glucocorticoids, the participant must be on a stable dose of ≤ 15 mg/day prednisone equivalent for at least 28 days prior to Day 1.
      • Note: If currently not on oral glucocorticoids, the participant must not have received oral glucocorticoids within 28 days prior to Day 1

Exclusion criteria

Exclusion Criteria:

  • History of failure of more than two anti-TNF therapies, prior history of failure of TYK2 and JAK inhibitors.

    • History of prior allergic reaction or intolerance to deucravacitinib.
    • History of primary failure of anti-IL17, anti-IL23 is excluded. Note that prior exposure to these agents is allowed for reasons other than primary failure, eg intolerance, insurance / access issues, etc).

      • Systemic agents other than anti-TNF or csDMARD (ie. MTX, leflunomide, sulfasalazine, hydroxychloroquine) must have ceased > 6 months prior to baseline.
      • Doses or >15mg daily prednisone or equivalent.
    • Severe cardiovascular, hepatic, or renal impairment.
    • History or evidence of outpatient active infection and/or febrile illness within 14 days prior to Day 1.
    • History of serious bacterial, fungal, or viral infection requiring hospitalization or parenteral antimicrobial treatment (eg, antibiotics antiviral, antifungal, or antiparasitic agents) within 60 days prior to Day 1.
    • Receipt of any therapy for chronic infection (eg, pneumocystis, herpes zoster, cytomegalovirus, invasive bacterial or fungal infections, or atypical mycobacteria) at screening.
    • Recent herpes zoster or herpes simplex infection or history of serious herpes zoster or herpes simplex infection defined as:
    • a) Herpes zoster or herpes simplex lesions within 30 days prior to randomization, OR
    • b) History of serious herpes zoster or serious herpes simplex infection, which includes, but it is not limited to, any episode of disseminated herpes simplex, multi- dermatomal herpes zoster, herpes encephalitis, ophthalmologic herpes, and/or recurrent herpes zoster (recurrent herpes zoster is defined as more than 2 episodes in the last 2 years).
    • Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status (eg, history of opportunistic infections [eg, Pneumocystis jirovecii pneumonia, histoplasmosis, or coccidioidomycosis], history of splenectomy, primary immunodeficiency).
    • Receipt of any within 60 days prior to Day 1 or plans to receive a live vaccine during the study or within 60 days after completing study treatment.
    • Evidence of, or positive testing for, virus or virus at screening.
    • Positive testing for 1 or 2 by antibody testing at screening.
    • History of active TB prior to the screening visit, signs or symptoms of active TB at screening, positive QuantiFERON®-TB Gold (or equivalent) test result or 2 successive indeterminate QuantiFERON®-TB Gold (or equivalent) test results at screening.
    • History of chronic or recurrent infectious disease.
    • History of VTE, MACE, active solid or history of malignancy \<5 years, any hematologic malignancy; history of multiple serious infections requiring hospitalization in the past 5 years, history of opportunistic infection, any condition which in the opinion of the investigator would pose a safety risk or inability to assess key endpoints in the study.
    • History of fibromyalgia/central sensitization, or other joint disease which in the opinion of the investigator would make musculoskeletal disease activity assessment challenging in the context of this study.
    • History of other inflammatory dermatosis which in the opinion of the investigator would make skin disease activity assessment challenging in the context of this study (eg atopic, contact dermatitis, etc).
    • Exclude use of topicals except for mild to mid-potency topical steroids for use only in cosmetically sensitive areas such as the face.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    established standard of care anti-TNF plus deucravacitinib

    Deucravacitinib will be administered in tablet form. Anti-TNF will be administered by injection.

    Drug: Deucravacitinib

  • Placebo comparator
    established standard of care anti-TNF plus placebo

    Placebo will be administered in tablet form. Anti-TNF will be administered by injection.

    Drug: Placebo

Interventions

  • Drug will be administered in tablet form.

  • DrugPlacebo

    Drug will be administered in tablet form.

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving a novel composite endpoint of BSA </= 1 AND SJC </= 1) OR (BSA </= 1 AND TJC </= 1) at 24 weeks

    Proportion of patients achieving a novel composite endpoint of BSA \</= 1 AND SJC \</= 1) OR (BSA \</= 1 AND TJC \</= 1) at 24 weeks

    Time frame: 24 weeks

Secondary outcomes

  1. Safety and tolerability, measured through adverse event reporting at baseline and weeks 5, 12, 24, and 48.

    Safety and tolerability, measured through adverse event reporting at baseline and weeks 5, 12, 24, and 48.

    Time frame: baseline and weeks 5, 12, 24, and 48

  2. Proportion of patients achieving Minimal Disease Activity (5/7 criteria) at weeks 24 and 48

    Reaching Minimal Disease Activity involves achieving 5 of 7 criteria. The 7 criteria include less than or equal to 1 tender joint count, patient global assessment of disease activity via Visual Analog Scale of less than or equal to 20, less than or equal to 1 swollen joint count, tender entheseal points of less than or equal to 1, Psoriatic Area and Severity Index of less than or equal to 1 OR Body Surface Area of less than or equal to 3 %, patient pain via Visual Analog Scale of less than or equal to 15, and Health Assessment Questionnaire - Disability Index of less than or equal to 0.5. The Minimal Disease Activity assessment will be done at weeks 24 and 48.

    Time frame: weeks 24 and 48

  3. Proportion of patients achieving Very Low Disease Activity (7/7 criteria) at weeks 24 and 48

    Very Low Disease Activity involves achieving 7 of 7 criteria. The 7 criteria include less than or equal to 1 tender joint count, patient global assessment of disease activity via Visual Analog Scale of less than or equal to 20, less than or equal to 1 swollen joint count, tender entheseal points of less than or equal to 1, Psoriatic Area and Severity Index of less than or equal to 1 OR Body Surface Area of less than or equal to 3 %, patient pain via Visual Analog Scale of less than or equal to 15, and Health Assessment Questionnaire - Disability Index of less than or equal to 0.5. The Very Low Disease Activity assessment will be done at weeks 24 and 48.

    Time frame: weeks 24 and 48

  4. Proportion of patients achieving Minimal Disease Activity - Skin (MDA with skin domain met) at weeks 24 and 48

    Minimal Disease Activity - Skin is determined by a Psoriatic Area and Severity Index of less than or equal to 1 OR Body Surface Area of less than or equal to 3 %. The Minimal Disease Activity - Skin assessment will be done at weeks 24 and 48.

    Time frame: weeks 24 and 48

  5. Percentage achieving Psoriatic Area and Severity Index 75/90/100, PASI < 1 BL at weeks 12, 24 and 48

    75%, 90% and 100% improvement in Psoriatic Area and Severity Index of less than 1 at baseline. This assessment will be done at weeks 12, 24 and 48.

    Time frame: baseline and weeks 12, 24 and 48

  6. Percentage achieving BSA < 1% (NPF definition) BL at weeks 12, 24 and 48

    Percentage achieving BSA \< 1% (NPF definition) BL at weeks 12, 24 and 48

    Time frame: baseline and weeks 12, 24 and 48

  7. Resolution of Spondyloarthritis Research Consortium of Canada at baseline and at weeks 24 and 48

    Resolution of Spondyloarthritis Research Consortium of Canada at baseline and at weeks 24 and 48

    Time frame: baseline and weeks 24 and 48

  8. Resolution of Leeds Enthesitis Index at baseline and at weeks 24 and 48

    Resolution of Leeds Enthesitis Index at baseline and at weeks 24 and 48

    Time frame: baseline and weeks 24 and 48

  9. Change from baseline Health Assessment Questionnaire - Disability Index at weeks 24 and 48

    Change from baseline Health Assessment Questionnaire - Disability Index at weeks 24 and 48

    Time frame: baseline and weeks 24 and 48

  10. Change from baseline Pruritis Numeric Rating Scale at weeks 12, 24 and 48

    Change from baseline Pruritis Numeric Rating Scale at weeks 12, 24 and 48

    Time frame: baseline and weeks 12, 24 and 48

  11. Change from baseline Joint pain Visual Analog Scale at weeks 12, 24 and 48

    Change from baseline Joint pain Visual Analog Scale at weeks 12, 24 and 48

    Time frame: baseline and weeks 12, 24 and 48

  12. Change from baseline patient global assessment of arthritis at weeks 12, 24 and 48

    Change from baseline patient global assessment of arthritis at weeks 12, 24 and 48

    Time frame: baseline and weeks 12, 24 and 48

  13. Change from baseline Dermatology Life Quality Index at weeks 12, 24 and 48

    Change from baseline Dermatology Life Quality Index at weeks 12, 24 and 48

    Time frame: baseline and weeks 12, 24 and 48

  14. Change from baseline Psoriatic Arthritis Impact of Disease 12-item Questionnaire and proportion achieving Patient Acceptable Symptom State cutoff at weeks 12, 24 and 48

    Change from baseline Psoriatic Arthritis Impact of Disease 12-item Questionnaire and proportion achieving Patient Acceptable Symptom State cutoff at weeks 12, 24 and 48

    Time frame: baseline and weeks 12, 24 and 48

Other outcomes

  1. Leed's enthesitis (resolution) BL at weeks 24 and 48

    Leed's enthesitis (resolution) BL at weeks 24 and 48

    Time frame: baseline and weeks 24 and 48

  2. Widespread pain index at baseline and at weeks 24 and 48

    Widespread pain index at baseline and at weeks 24 and 48

    Time frame: baseline and weeks 24 and 48

  3. International Dermatology Outcome Measure Musculoskeletal Questionnaire instrument (instrument validation) at baseline and at weeks 12, 24 and 48

    International Dermatology Outcome Measure Musculoskeletal Questionnaire instrument (instrument validation) at baseline and at weeks 12, 24 and 48

    Time frame: baseline and weeks 12, 24 and 48

  4. Cardiometabolic biomarker evaluation at baseline, week 24 and week 48

    Cardiometabolic biomarker evaluation includes tests for lipids, glycoprotein acetylation, fasting glucose, insulin levels, hemoglobin A1c, C-Reactive Protein, homeostatic model assessment for insulin resistance. These tests will be done at baseline, week 24 and week 48

    Time frame: baseline, week 24 and week 48

  5. Symptom Severity Scale (used for post-hoc stratification analyses) at baseline and at weeks 24 and 48

    Symptom Severity Scale (used for post-hoc stratification analyses) at baseline and at weeks 24 and 48

    Time frame: baseline and at weeks 24 and 48

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Of 33 phase 4 interventional studies under Arthritis, Psoriatic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 37. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 12, 2025
StartActual
Jun 16, 2026
Primary completionEst.
Dec 15, 2027
CompletionEst.
Dec 15, 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07280702
Responsible party
Joseph Merola (Professor & Chair-Dermatology, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Dec 12, 2025
Start date
Jun 16, 2026
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Aleuna Lee, PhD, CCRC
Contact
aleuna.lee@utsouthwestern.edu
214-645-8968
Joseph F. Merola, MD MMSc
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion